Red Meat: Risk for T2D

被引：0
作者：
不详
机构：
来源：
DIABETES STOFFWECHSEL UND HERZ | 2024年 / 33卷 / 01期
关键词：
INSULIN GLARGINE; EFFICACY; SAFETY; COMBINATION; ADULTS; LISPRO; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：70
相关论文
共 9 条
[1]   Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial [J].
Aroda, Vanita R. ;
Rosenstock, Julio ;
Wysham, Carol ;
Unger, Jeffrey ;
Bellido, Diego ;
Gonzalez-Galvez, Guillermo ;
Takami, Akane ;
Guo, Hailing ;
Niemoeller, Elisabeth ;
Souhami, Elisabeth ;
Bergenstal, Richard M. .
DIABETES CARE, 2016, 39 (11) :1972-1980
[2]   Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study [J].
Blevins, T. C. ;
Dahl, D. ;
Rosenstock, J. ;
Ilag, L. L. ;
Huster, W. J. ;
Zielonka, J. S. ;
Pollom, R. K. ;
Prince, M. J. .
DIABETES OBESITY & METABOLISM, 2015, 17 (08) :726-733
[3]   Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study [J].
Blevins, Thomas C. ;
Barve, Abhijit ;
Sun, Bin ;
Raiter, Yaron ;
Aubonnet, Patrick ;
Muniz, Rafael ;
Athalye, Sandeep ;
Ankersen, Michael .
DIABETES OBESITY & METABOLISM, 2019, 21 (01) :129-135
[4]   Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study [J].
Blevins, Thomas C. ;
Barve, Abhijit ;
Sun, Bin ;
Ankersen, Michael .
DIABETES OBESITY & METABOLISM, 2018, 20 (08) :1944-1950
[5]   Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study [J].
Derwahl, Karl-Michael ;
Bailey, Timothy S. ;
Wernicke-Panten, Karin ;
Ping, Lin ;
Pierre, Suzanne .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (01) :49-58
[6]   Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1) [J].
Garg, Satish K. ;
Wernicke-Panten, Karin ;
Wardecki, Marek ;
Kramer, Daniel ;
Delalande, Francois ;
Franek, Edward ;
Sadeharju, Karita ;
Monchamp, Travis ;
Mukherjee, Bhaswati ;
Shah, Viral N. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (02) :85-95
[7]   Efficacy and Safety of Biosimilar*SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study [J].
Garg, Satish K. ;
Wernicke-Panten, Karin ;
Rojeski, Maria ;
Pierre, Suzanne ;
Kirchhein, Yvonne ;
Jedynasty, Krystyna .
DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (09) :516-526
[8]   Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study) [J].
Rosenstock, J. ;
Hollander, P. ;
Bhargava, A. ;
Ilag, L. L. ;
Pollom, R. K. ;
Zielonka, J. S. ;
Huster, W. J. ;
Prince, M. J. .
DIABETES OBESITY & METABOLISM, 2015, 17 (08) :734-741
[9]  
wockhardt, About us
1